Climate Change Data

Environmental Metrics

ESG Focus Areas

• Innovation
• Patients
• People
• Communities
• Planet
• Governance

Climate Goals & Targets

Supply Chain Management

Climate-Related Risks & Opportunities

Environmental Metrics

ESG Focus Areas

• Patient Safety
• Product Quality
• Access & Affordability
• Patient Advocacy
• Employee Equity, Diversity & Inclusion
• Employee Health & Safety
• Workforce Management
• Climate Change Risks & Management
• Energy Management
• Product Stewardship
• Waste Management
• Water Management
• Community Relations
• Ethical Practices & Corporate Behavior
• Governance Structures & Mechanisms
• Human Rights
• Management of the Legal & Regulatory Environment
• Privacy & Data Protection
• Risk Management & Business Continuity
• Transparency

Environmental Achievements

• Purchased 1,988 megawatt-hours (MWh) of renewable electricity, which avoided an estimated 465 MT of carbon dioxide equivalent (CO2e).
• Installed additional electric vehicle charging ports, bringing our total to 11.
• Partnered with our waste services vendor to launch a medical waste takeback program.
• Diverted 950 pounds of plastic waste from landfill, including circularizing 75% into new lab products through partnership with Polycarbin.

Social Achievements

• Total turnover was 13.3%, which is below the U.S. and global averages for our industry.
• Maintained a high engagement score of 86% in our employee engagement survey.
• Launched Declaring and Repairing Breakdowns, a mandatory employee education program.
• Launched a new I&D Employee Resource Group (ERG), UltraAPAC.
• Launched a partnership with Disability Solutions on outcomes for talent with disabilities.
• Approved $4.27 million in company-sponsored charitable donations and grants.
• Provided funding to EURORDIS, Razom for Ukraine and Save the Children to support relief efforts in Ukraine and the broader refugee crisis.
• Over 500 patients in over 40 countries have been approved for access to Ultragenyx treatments through various global expanded access and patient assistance programs since 2013.

Governance Achievements

• 100% of full-time employees provided written or digital acknowledgment of the Global Code of Conduct.
• 100% of full-time employees have received training on the Global Code of Conduct within the last three years.
• Ultragenyx’s Healthcare Compliance Manual was translated into Spanish, Portuguese, French and German.
• All reported complaints related to potential breaches to our Code of Conduct and incidents of discrimination or harassment were investigated and promptly addressed.
• Became a member of Rx-360 (The International Pharmaceutical Supply Chain Consortium) and began to participate in the Rx-360 Joint Audit Program.

Climate Goals & Targets

Supply Chain Management

Responsible Procurement

• Global Standard for Suppliers

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI, SASB

UN Sustainable Development Goals

• Goal 3: Good Health and Well-being
• Goal 4: Quality Education
• Goal 5: Gender Equality
• Goal 10: Reduced Inequalities

Ultragenyx focuses on advancing health equity by developing therapies for rare and ultrarare diseases, advocating for broad access to screening and treatment, advancing employee health, safety and wellness, promoting rare disease education and awareness, expanding access to STEAM education opportunities, and promoting gender equality in the workplace.

Environmental Metrics

ESG Focus Areas

• Innovation
• Patients
• People
• Communities
• Planet
• Governance

Environmental Achievements

• Purchased 1,955+ megawatt-hours (MWh) of renewable electricity, which avoided an estimated 473 metric tons (MT) of carbon dioxide equivalent (CO2e); installed additional electric vehicle charging ports, bringing our total to 38
• Strengthened waste vendor partnerships to expand diversion and circularization programs
• Launched My Green Lab certification pilot program at our Translational Sciences lab in Novato, California

Social Achievements

• Total turnover was 15.5%, which is below the U.S. and global averages for our industry
• Maintained a high engagement score of 86% in our employee engagement survey
• Women accounted for 60% of promotions globally, while U.S. employees who self-identified as racially or ethnically diverse represented 46% of U.S. promotions
• Launched an inaugural global “Days of Service” initiative
• More than 4,700 patients have received Ultragenyx treatments through commercial or expanded access in more than 50 countries

Governance Achievements

• All reported complaints related to potential breaches to our code of conduct and incidents of discrimination or harassment were investigated and promptly addressed, as appropriate
• Published a formal Global Human Rights policy
• Continued efforts to comply with the U.S. Department of Treasury’s OFAC regulations

Climate Goals & Targets

Environmental Challenges

• Challenges in Ultrarare Disease Drug Development: substantial regulatory and commercial hurdles in creating treatments for ultrarare diseases
• Delays in diagnosis can result in patients receiving ineffective treatments and unnecessary testing, as well as the possibility of missing their opportunity for effective treatment altogether
• Payers often decline reimbursement of genetic testing, which is critical to a proper diagnosis in rare and ultrarare disease areas

Mitigation Strategies

• Ultragenyx is proposing the UltraOrphan Drug Act, legislation intended to implement a new framework for incentivizing development of therapies for diseases with very small patient populations
• Ultragenyx is focused on differentially diagnosing 9 different rare diseases to give physicians information that will support clinically-appropriate decision making and disease management.
• Ultragenyx sponsored testing programs

Supply Chain Management

Supplier Audits: 6 RX-360 audit reports licensed in 2023

Responsible Procurement

• Global Standard for Suppliers
• zero-tolerance stance on modern slavery

Climate-Related Risks & Opportunities

Physical Risks

• Not disclosed

Transition Risks

• Not disclosed

Opportunities

• Not disclosed

Reporting Standards

Frameworks Used: GRI, SASB

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

• Goal 3: Good Health and Well-being
• Goal 8: Decent Work and Economic Growth
• Goal 10: Reduced Inequalities
• Goal 13: Climate Action
• Goal 17: Partnerships for the Goals

Ultragenyx’s mission, vision and values align with several of the UN SDGs.

Sustainable Products & Innovation

• Not disclosed

Awards & Recognition

• Top Places to Work by the Boston Globe
• Cultural Excellence Awards from Top Work Places
• Healthcare’s Best Companies to Work For by U.S. News & World Report
• Best Places for Working Families®